Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biomarkers for early detection of kidney disease: a call for pathophysiological relevance

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Complement activation is a crucial driver of acute kidney injury in rhabdomyolysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

    Research output: Contribution to journalJournal articleResearchpeer-review

  • DAPA-CKD Trial Committees and Investigators
View graph of relations

Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to kidney failure. In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, dapagliflozin reduced the risk of kidney failure and prolonged survival in participants with chronic kidney disease with and without type 2 diabetes, including those with IgA nephropathy. Participants with estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g (22.6-565 mg/mol) were randomized to dapagliflozin 10mg or placebo, as adjunct to standard care. The primary composite endpoint was a sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from a kidney disease-related or cardiovascular cause. Of 270 participants with IgA nephropathy (254 [94%] confirmed by previous biopsy), 137 were randomized to dapagliflozin and 133 to placebo, and followed for median 2.1 years. Overall, mean age was 51.2 years; mean eGFR, 43.8 mL/min/1.73m2; and median urinary albumin-to-creatinine ratio, 900 mg/g. The primary outcome occurred in six (4%) participants on dapagliflozin and 20 (15%) on placebo (hazard ratio, 0.29; 95% confidence interval, 0.12, 0.73). Mean rates of eGFR decline with dapagliflozin and placebo were -3.5 and -4.7 mL/min/1.73m2/year, respectively. Dapagliflozin reduced the urinary albumin-to-creatinine ratio by 26% relative to placebo. Adverse events leading to study drug discontinuation were similar with dapagliflozin and placebo. There were fewer serious adverse events with dapagliflozin, and no new safety findings in this population. Thus, in participants with IgA nephropathy, dapagliflozin reduced the risk of chronic kidney disease progression with a favorable safety profile.

Original languageEnglish
JournalKidney International
Volume100
Issue number1
Pages (from-to)215-224
Number of pages10
ISSN0085-2538
DOIs
Publication statusPublished - Jul 2021

    Research areas

  • Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glomerulonephritis, IGA/drug therapy, Glucosides, Humans, Kidney, Middle Aged, Renal Insufficiency, Chronic/complications, Sodium-Glucose Transporter 2 Inhibitors, chronic kidney disease, dapagliflozin, DAPA-CKD, sodium-glucose cotransporter inhibitor, IgA nephropathy, randomized controlled clinical trial

ID: 66945103